Thursday, August 15, 2024 The Antiviral Tecovirimat Is Safe but Did Not Improve Clade I Mpox Resolution in Democratic Republic of the Congo Colorized transmission electron micrograph of mpox virus particles (red/yellow) found within infected VERO E6 cells (brown). The virus particles are in various stages of maturity, which accounts for differences in shape. Captured at the NIAID Integrated Research Facility in Fort Detrick, Maryland. Credit: NIAID The antiviral drug tecovirimat did not reduce the duration of mpox lesions among children and adults with clade I mpox in the Democratic Republic of the Congo, based on an initial analysis of data from the PALM007 trial. Further analyses and detailed results will be released through scientific channels. Additional studies of tecovirimat for mpox treatment in other populations are ongoing. Learn More National Institute of Allergy and Infectious Diseases  |  National Institutes of Health

---

Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. Your subscription may be removed if you do not open our emails for a six-month period. 

This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).

                           

---

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107